Aethlon Medical, Inc. — Form 10-Q Summary
Business context and reporting period
For the quarter and nine months ended December 31, 2011 (fiscal Q3 and year-to-date fiscal 2012). Aethlon develops medical devices based on its ADAPT platform, including the Hemopurifier. The company reported its first revenue, from a DARPA-funded sepsis-device development contract, and said it had emerged from the development stage. Hemopurifier human trials and FDA approval remained outstanding.
Financial results and position
| Metric | Three months ended Dec. 31, 2011 | Nine months ended Dec. 31, 2011 |
|---|---|---|
| Revenue | $958,075 | $958,075 |
| Operating expenses | $1,299,403 | $3,214,839 |
| Operating loss | $341,328 | $2,256,764 |
| Net loss | $574,718 | $3,614,095 |
| Loss per share, basic and diluted | $0.01 | $0.04 |
| Cash used in operating activities | Not provided for quarter | $1,101,086 |
Revenue was recognized on substantive DARPA milestones; the filing reports no separate cost-of-revenue figure, so a gross margin is not clear. At December 31, cash was $354,804, total current assets were $758,170, and current liabilities were $7,010,214, yielding negative working capital of approximately $6.252 million. Total assets were $903,023 and stockholders’ deficit was $6.107 million. Current liabilities included $2.463 million of convertible notes, net of discounts, $584,796 of notes payable, $1.251 million of derivative liabilities, and $617,570 due to related parties.
Changes versus prior comparable periods
- Quarterly revenue increased from zero to $958,075; quarterly net loss narrowed from $1.868 million to $575,000. Operating expenses rose 24%, mainly from DARPA-related supplies and equipment and higher professional fees.
- Nine-month revenue increased from zero to $958,075; net loss narrowed from $8.105 million to $3.614 million. Operating expenses decreased 11%, primarily reflecting lower stock-based compensation, partly offset by higher DARPA-related costs and HCV-trial consulting.
- Nine-month operating cash use improved from $1.513 million to $1.101 million. Cash increased from $15,704 at March 31, 2011 to $354,804 at December 31, 2011, principally through financing proceeds and collection of secured notes receivable.
- Common shares outstanding increased from 77.5 million at March 31 to 109.0 million at December 31; the filing reports 111.6 million outstanding as of February 15, 2012. Note conversions and warrant activity contributed to dilution.
Outlook, risks, and unusual items
- The DARPA fixed-price award has potential payments of $6.794 million over five years, including up to $1.975 million in year one. Only year one was formally contracted; years two through five are at DARPA’s option. Payments depend on milestone performance and government acceptance. Three of eight year-one milestones were achieved in the quarter.
- Management said available resources were insufficient for fiscal 2012 requirements and additional debt or equity financing was needed. It believed existing cash, DARPA funding, and anticipated financing could meet short-term needs, but gave no assurance financing would be available on acceptable terms. The filing cites a minimum operating need of approximately $180,000 per month and expects continued losses and negative cash flows.
- The filing states that recurring losses, defaults on debt, negative working capital, and a $52.086 million accumulated deficit raise substantial doubt about the company’s ability to continue as a going concern. Approximately $1.792 million of note principal was past due, with $639,958 of related accrued interest; certain debt terms and maturities were subject to negotiation or extension.
- The DARPA contract generated a $1.596 million noncash gain from the change in fair value of derivative liabilities during the nine-month period. Debt extinguishment losses were zero in 2011, versus $3.190 million in the prior-year period. Accrued registration-related liquidated damages were $437,800.
- Management reported disclosure controls and procedures were not effective at period-end. It reported no material change in internal control over financial reporting during the quarter.
- After quarter-end, the company shipped a diagnostic product to a life sciences company for $1,432, its first commercial sale; payment was received in February 2012 and the sale was to be recorded in the March quarter. The Hemopurifier still required human-trial and regulatory progress; risks also included patent-life uncertainty, financing needs, market acceptance, competition, and product liability.
Key facts investors should verify
- Progress toward DARPA milestones, government acceptance and payment, and whether the agency exercises later-year options.
- Availability, terms, and timing of additional financing, and the company’s ability to meet near-term obligations given its cash position and debt defaults.
- Debt balances and maturities, accrued interest, any extensions or settlements, and the extent of further share issuance from conversions, warrants, or financing.
- Regulatory status of the Hemopurifier, including the IDE and path to human trials, as well as subsequent commercial sales beyond the initial $1,432 shipment.
- Remediation of ineffective disclosure controls and the company’s continuing ability to operate as a going concern.